Targeting the eicosanoid pathway in hepatocellular carcinoma.

Razdan, Anshuli; Main, Nathan M; Chiu, Vincent; Shackel, Nicholas A; de Souza, Paul; Bryant, Katherine; Scott, Kieran F

Razdan, Anshuli; Main, Nathan M; Chiu, Vincent; Shackel, Nicholas A; de Souza, Paul; Bryant, Katherine; Scott, Kieran F.

Affiliation

Razdan A; School of Medicine, Western Sydney University Sydney, NSW, Australia.
Main NM; Department of Medical Oncology, Ingham Institute for Applied Medical Research Sydney, NSW, Australia.
Chiu V; Gastroenterology and Liver Laboratory, Ingham Institute for Applied Medical Research Sydney, NSW, Australia.
Shackel NA; Gastroenterology and Liver Laboratory, Ingham Institute for Applied Medical Research Sydney, NSW, Australia.
de Souza P; Gastroenterology and Liver Laboratory, Ingham Institute for Applied Medical Research Sydney, NSW, Australia.
Bryant K; School of Medicine, Western Sydney University Sydney, NSW, Australia.
Scott KF; Department of Medical Oncology, Ingham Institute for Applied Medical Research Sydney, NSW, Australia.

Am J Cancer Res ; 11(6): 2456-2476, 2021.

Article de En | MEDLINE | ID: mdl-34249410

Mots clés

Hepatocellular carcinoma; NAFLD; cirrhosis; cyclooxygenase; cytochrome P450; eicosanoids; fibrosis; inflammation; lipoxygenase; phospholipase A2

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Type d'étude: Prognostic_studies Langue: En Journal: Am J Cancer Res Année: 2021 Type de document: Article Pays d'affiliation: Australie

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google